15.10.2012 - Patients in Australia and New Zealand will also receive Almirall's Aclidinium against the lung disease COPD. Invida is the licensing partner.
After the approval of Aclidinium by the European Commission in July and the following deal with Italian Menarini Group to commercialise the drug in most of Europe in July, Barcelona-based Almirall S.A. has inked a marketing partnership with Invida Holdings Private Limited, a member of the Menarini Group, to sell the drug on the fifth continent . Invida gains the commercial rights for Aclidinium in Australia and New Zealand, with the deal including both monotherapy and combination therapy (with Formoterol). Both treatments work against Chronic Obstructive Pulmonary Disease (COPD), where the drug relieves the tension in the muscles around the lungs to improve airflow.
COPD makes breathing difficult and is often caused by cigarette smoking. It is estimated that around 2 million people in Australia suffer from the disease, where it is the sixth most common cause of death among men and seventh among women, Almirall said. Financial details of the agreement have not been disclosed. Eduardo Sanchiz, Chief Executive Officer of Almirall, states: "Together with Invida, we will be able to offer this novel therapy in Australia and New Zealand for COPD. With this new agreement Aclidinium, via partners or Almirall's own salesforce, now has access to over 80% of the COPD world market including the US, Japan, Korea and Europe, where we already have secured four license agreements in total." In Germany and Denmark, Aclidinium bromide is already on the market. It works as a long-acting inhaled muscarinic antagonist - sometimes referred to as an anticholinergic -, which has a long residence time at M3 receptors and a shorter residence time at M2 receptors. It is designed to be rapidly broken down in plasma into two major inactive metabolites, explaining its high topical efficacy but low propensity for systemic anticholinergic effects. When taken by inhalation, Aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction.
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more